Biotech
BOSTON -- The Biotech Mailbag marches on, even with a Thanksgiving turkey hangover.
This week: Pipex Pharmaceuticals(PP) Hythiam(HYTM) Amgen(AMGN) Isis Pharmaceuticals(ISIS).Anand J. writes to ask about Pipex Pharmaceuticals: "Any thoughts on this company with several late-stage drugs? Their lead drug Coprexa is very close to an [FDA] filing. Also, management holds a lot of the company stock and runs a tight ship, which is always a good sign." Regular readers know that I place a lot of emphasis (perhaps too much) on the quality and trustworthiness of management. This is especially important in small-cap, thinly traded biotech stocks like Pipex. Steve Kanzer runs Pipex and is the largest shareholder, owning just under half the company. This is a photo montage from Time that includes a shot of Kanzer taken last May during an FDA advisory panel meeting convened to discuss a drug from Dor BioPharma(DORB), where Kanzer was vice chairman at the time. He has since resigned from Dor's board. Scroll to photo No. 4 to see Kanzer being physically restrained and forcibly removed from the meeting. Perhaps he had too much coffee that day. I hope so, but I have my doubts. Suffice to say, he's not exactly high-quality biotech management material in my book. Kanzer factored into another old story of mine on Dor, which also makes me feel uneasy about his leadership.
TheStreet Premium Services
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn MoreOptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn MoreReal Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn MoreStocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,393.45 | 1,310.33 | 2,827.34 | 15.81 |
Oil *
101.78
|
|
DOWN
26.41 |
DOWN
2.99 |
DOWN
10.02 |
DOWN
0.44 |
10 Yr
1.58%
SPDR Gold
151.62
|
|
-0.21%
|
-0.23%
|
-0.35%
|
-2.71%
|
Data delayed 20 minutes |


Connect with TheStreet